{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:35:36Z","timestamp":1790656536633,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"DOI":"10.1245\/s10434-026-20388-8","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T17:21:19Z","timestamp":1787419279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytoplasmic Morphology Predicts the Tumor Immune Microenvironment and Recurrence in Localized Clear Cell Renal Cell Carcinoma"],"prefix":"10.1245","author":[{"given":"Yoshiyuki","family":"Furukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Miyai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koetsu","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shinchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"20388_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/jjco\/hyz013","volume":"49","author":"T Osawa","year":"2019","unstructured":"Osawa T, Takeuchi A, Kojima T, et al. Overview of current and future systemic therapy for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2019;49:395\u2013403.","journal-title":"Jpn J Clin Oncol"},{"key":"20388_CR2","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/cncr.34180","volume":"128","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128:2085\u201397.","journal-title":"Cancer"},{"key":"20388_CR3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390.","journal-title":"N Engl J Med"},{"key":"20388_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116\u201327.","journal-title":"N Engl J Med"},{"key":"20388_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683\u201394.","journal-title":"N Engl J Med"},{"key":"20388_CR6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.4111\/kju.2010.51.9.596","volume":"51","author":"JM Kim","year":"2010","unstructured":"Kim JM, Song PH. Comparison of partial and radical nephrectomy for pT1b renal cell carcinoma. Korean J Urol. 2010;51:596\u2013600.","journal-title":"Korean J Urol"},{"key":"20388_CR7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1464-410X.2008.08230.x","volume":"103","author":"S Joniau","year":"2009","unstructured":"Joniau S, Vander Eeckt K, Van Poppel H. Outcome of nephron-sparing surgery for T1b renal cell carcinoma. BJU Int. 2009;103:1344\u20138.","journal-title":"BJU Int"},{"key":"20388_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3892\/ol.2014.2670","volume":"9","author":"K Ito","year":"2015","unstructured":"Ito K, Seguchi K, Asano T, et al. Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma. Oncol Lett. 2015;9:302\u20136.","journal-title":"Oncol Lett"},{"key":"20388_CR9","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/cas.14019","volume":"110","author":"S Mikami","year":"2019","unstructured":"Mikami S, Mizuno R, Kosaka T, et al. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. Cancer Sci. 2019;110:1820\u20138.","journal-title":"Cancer Sci"},{"issue":"7","key":"20388_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/jjco\/hyaf054","volume":"55","author":"Y Arai","year":"2025","unstructured":"Arai Y, Miyai K, Furukawa Y, et al. Impact of tumor-infiltrating immune cells expressing PD-1 and those expressing PD-L1 on recurrence and prognosis in pathological T1b clear cell renal cell carcinoma. Jpn J Clin Oncol. 2025;55(7):797\u2013806.","journal-title":"Jpn J Clin Oncol"},{"key":"20388_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002922","volume":"9","author":"T Yoshida","year":"2021","unstructured":"Yoshida T, Ohe C, Kuroda N, et al. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. J Immunother Cancer. 2021;9:e002157.","journal-title":"J Immunother Cancer"},{"key":"20388_CR12","volume-title":"TNM classification of malignant tumours","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 8th edn. Chichester: Wiley-Blackwell; 2017.","edition":"8"},{"key":"20388_CR13","volume-title":"WHO classification of tumours of the urinary system and male genital organs","author":"H Moch","year":"2022","unstructured":"Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. 5th edn. Lyon: IARC; 2022.","edition":"5"},{"key":"20388_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/cncr.21206","volume":"104","author":"S Sengupta","year":"2005","unstructured":"Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104:511\u201320.","journal-title":"Cancer"},{"key":"20388_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"key":"20388_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/biomedicines10020323","volume":"10","author":"C Ohe","year":"2022","unstructured":"Ohe C, Yoshida T, Ikeda J, et al. Histologic-based tumor-associated immune cells status in clear cell renal cell carcinoma correlates with gene signatures related to cancer immunity and clinical outcomes. Biomedicines. 2022;10:323.","journal-title":"Biomedicines"},{"key":"20388_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/path.5532","volume":"252","author":"H Nilsson","year":"2020","unstructured":"Nilsson H, Lindgren D, Mandahl, et al. Features of increased malignancy in eosinophilic clear cell renal cell carcinoma. J Pathol. 2020;252:184\u201396.","journal-title":"J Pathol"},{"key":"20388_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.juro.2011.03.113","volume":"186","author":"K Ito","year":"2011","unstructured":"Ito K, Yoshii H, Saito K, et al. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol. 2011;186:430\u20135.","journal-title":"J Urol"},{"key":"20388_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298\u2013306.","journal-title":"Nat Rev Cancer"},{"key":"20388_CR20","first-page":"3569","volume":"53","author":"A Mackensen","year":"1993","unstructured":"Mackensen A, Ferradini L, Carcelain G, et al. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 1993;53:3569\u201373.","journal-title":"Cancer Res"},{"key":"20388_CR21","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","volume":"29","author":"SM Mahmoud","year":"2011","unstructured":"Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949\u201355.","journal-title":"J Clin Oncol"},{"key":"20388_CR22","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1073\/pnas.0611618104","volume":"104","author":"P Sharma","year":"2007","unstructured":"Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104:3967\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"key":"20388_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1200\/JCO.2010.30.5425","volume":"29","author":"B Mlecnik","year":"2011","unstructured":"Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610\u20138.","journal-title":"J Clin Oncol"},{"key":"20388_CR24","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","volume":"21","author":"NA Giraldo","year":"2015","unstructured":"Giraldo NA, Becht E, Pag\u00e8s F, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21:3031\u201340.","journal-title":"Clin Cancer Res"},{"key":"20388_CR25","first-page":"19","volume":"9","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Zhu Y, Liu Z, et al. Deep spatial proteomics reveals a suppressive immune niche linked to immune evasion in renal cell carcinoma. Cancer Drug Resist. 2026;9:19.","journal-title":"Cancer Drug Resist"},{"key":"20388_CR26","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1442-2042.2006.01563.x","volume":"13","author":"K Ito","year":"2006","unstructured":"Ito K, Asano T, Yoshii H, et al. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 2006;13:1365\u201370.","journal-title":"Int J Urol"},{"key":"20388_CR27","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/jjco\/hyy154","volume":"49","author":"K Ito","year":"2019","unstructured":"Ito K, Masunaga A, Yoshii H, et al. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. Jpn J Clin Oncol. 2019;49:610\u20136.","journal-title":"Jpn J Clin Oncol"},{"key":"20388_CR28","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large multicenter study. J Clin Oncol. 2009;27:5794\u20139.","journal-title":"J Clin Oncol"},{"key":"20388_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.juro.2011.10.026","volume":"187","author":"Y Ohno","year":"2012","unstructured":"Ohno Y, Nakashima J, Ohori M, et al. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol. 2012;187:411\u20137.","journal-title":"J Urol"},{"key":"20388_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883\u201392.","journal-title":"N Engl J Med"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20388-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T17:21:22Z","timestamp":1787419282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20388-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":30,"alternative-id":["20388"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20388-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the National Defense Medical College ethical review board (approval no. 5322).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained by an opt-out form published on our website. Patients were given the opportunity to decline to have their clinical records and paraffin-embedded slides of surgical specimens used for research.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}